Mirum Pharmaceuticals, Inc. MIRM Livmarli — Development or regulatory milestones incurred
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept mirm:DevelopmentOrRegulatoryMilestonesIncurred.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s livmarli — development or regulatory milestones incurred.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s livmarli — development or regulatory milestones incurred?
- Mirum Pharmaceuticals, Inc. (MIRM) reported livmarli — development or regulatory milestones incurred of $0 in Q1 2026.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s livmarli — development or regulatory milestones incurred?
- Over 2 years (2021 to 2024), Mirum Pharmaceuticals, Inc.'s livmarli — development or regulatory milestones incurred has grown at a -100.0% compound annual growth rate (CAGR), from $32M to $0.
- What does livmarli — development or regulatory milestones incurred mean?
- Tracks the costs recognized when specific development or regulatory targets are reached for a product. This metric helps investors understand the timing and magnitude of expenses tied to the advancement of the drug pipeline.